GRAL at a glance
GRAIL, Inc. (GRAL, SEC CIK 1699031) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), GRAIL, Inc. (GRAL) reported revenue of $147.2 million (up 17.2% from FY2024) and a net loss of $408.4 million. Diluted EPS was -$11.11.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding GRAIL, Inc. (GRAL) shares worth $2.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Freidin Aaron on November 16, 2026 of 100 shares at $112.53 per share.
- In the last 90 days, GRAL insiders reported 0 open-market purchases ($0) and 27 open-market sales ($15.2M) on Form 4, a net sale of $15.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $147.2M
- +17.2% vs prior year
- Insiders · 90 days
- 0 buys · 27 sells
- Net −$15.2M
- 13F holders
- 31 funds
- $2.1B · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Commercial-stage healthcare company focused on multi-cancer early detection (MCED) via Galleri blood-based screening test
- New emphasis: 2026 PMA submission to FDA based on PATHFINDER 2 and NHS-Galleri Trial data; Medicare coverage pathway established under new federal law
- Strategic shift: Scaling commercial operations with automated Galleri version launched late 2024; expanding international presence in Israel, Canada, South Korea
- Notable metric: Over 475,000 Galleri tests sold by end of 2025, processing >800,000 total tests across clinical and commercial programs
- Distinctive fact: NHS-Galleri Trial results in 140,000+ participants showed >20% stage 4 cancer diagnosis reduction despite missing primary endpoint, informing ongoing UK NHS evaluation
Risk Factors
- Regulatory risk from Illumina Supply Agreement royalties commencing December 24, 2026, potentially increasing costs and impacting margins
- U.S. market concentration with majority Galleri sales domestically, risk from limited broad reimbursement and pricing pressure from discounts and rebates
- Operational risk from scaled platform leveraged by demand growth, but reduced investment in DAC and other product development beyond Galleri
- Competitive risk from need to drive Galleri awareness post-positive study results, facing market competition in cancer screening tests
- Financial risk from goodwill and intangible assets impairment review triggered by valuation changes since Illumina acquisition and pushdown accounting adjustments
Management Discussion & Analysis
- Revenue not explicitly stated; commercial Galleri tests sold: 475,000 through 2025, including 185,000 in 2025
- Net losses $408.4M (2025) vs $2.0B (2024) vs $1.5B (2023); Adjusted EBITDA $(320.6)M (2025) vs $(483.5)M (2024)
- Equity raises: $311.3M net from $325M PIPE in Oct 2025; $107.5M net from ATM program shares in 2025; $110M equity investment from Samsung pending
- Management expects continued operating losses due to R&D and commercialization investment; FDA PMA submission ongoing with trial results supporting product performance
AI summary of the GRAL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $37.5M, up $1.3M YoY, driven by screening revenue $37.3M, up 14%
- Adjusted gross margin 42% vs 55% YoY, with screening cost ratio up approximately 11 percentage points
- Screening best performer: Galleri volume up 24%; development services revenue fell 92% to $0.1M
- Cash and securities $788.7M at September 30; operating cash used $242.5M versus $235.2M YoY
- Samsung financing generated $109.0M; FDA decision expected by early first quarter 2027, broader reimbursement remains unavailable
Risk Factors
- New securities litigation risk: June 2026 Robbins class action and Augitto derivative action allege misleading NHS-Galleri Trial disclosures
- New intellectual-property risk: September 2026 Clinical Genomics lawsuit alleges Galleri infringes two U.S. patents
- FDA approval risk updated: September 2026 advisory panel supported Galleri, but FDA may delay, restrict, or deny PMA approval
- Pricing risk updated: September 2026 promotional reductions may increase demand while lowering average selling prices and margins
- Regulatory risk reduced: SEC investigation into Illumina’s GRAIL-related disclosures closed May 9, 2025
AI summary of the GRAL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- GRAIL announced financial results for Q3 ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, cash flow and guidance details
Item EX-99.1: Item EX-99.1
- Q3 revenue $37.5M, up 4%, led by Galleri revenue growth of 14% to $37.3M
- Galleri volume exceeded 56,000 tests, up approximately 24%; nine-month volume surpassed 174,000, up 36%
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 26% to $44.7M; Galleri revenue increased 24% to $42.6M on test volume growth of 35% to over 61,000
- First-half Galleri revenue reached $82.5M, up 30%, while volume exceeded 117,000, up 42%
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
- Financial results and management commentary contained in Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- 35,076,394 shares represented, establishing quorum from 42,916,593 eligible shares
- Sarah Krevans and Steven Mizell elected Class II directors through 2029
AI summaries of GRAL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GRAL
Don't miss the next GRAL filing
- Alerts as it files. A push when GRAL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GRAL, by share count.
- Ask anything. An AI agent that reads every GRAL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Freidin Aaron | Sell | Nov 16, 2026 | 100 | $112.53 |
| Freidin Aaron | Sell | Nov 16, 2026 | 500 | $104.97 |
| Freidin Aaron | Sell | Nov 16, 2026 | 1,200 | $107.45 |
| Freidin Aaron | Sell | Nov 16, 2026 | 400 | $109.86 |
| Freidin Aaron | Sell | Nov 16, 2026 | 500 | $108.83 |
| Freidin Aaron | Sell | Nov 16, 2026 | 300 | $106.11 |
| Ofman Joshua J. | Sell | Oct 15, 2026 | 3,400 | $135.44 |
| Ofman Joshua J. | Sell | Oct 15, 2026 | 1,000 | $134.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $125.6M | $147.2M |
| Operating Income | -$1.5B | -$2.2B | -$562.2M |
| Net Income | -$1.5B | -$2.0B | -$408.4M |
| Op. Margin | - | -1743.0% | -382.0% |
| Net Margin | - | -1613.9% | -277.5% |
| Balance Sheet | |||
| Total Assets | - | $3.0B | $2.9B |
| Equity | - | $2.5B | $2.6B |
| ROE | - | -81.0% | -15.8% |
| Per Share | |||
| EPS | - | $-63.54 | $-11.11 |
| Cash Flow | |||
| Operating CF | -$595.8M | -$577.2M | -$299.0M |
| CapEx | $12.9M | $5.2M | $909K |
Source: XBRL data in GRAIL, Inc. (GRAL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GRAL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $2.08B |
| Q2 2026 | 31 | $963.4M |
| Q1 2026 | 33 | $645.7M |
| Q4 2025 | 31 | $1.06B |
| Q3 2025 | 31 | $582.0M |
| Q2 2025 | 29 | $526.0M |
| Q1 2025 | 25 | $170.3M |
| Q4 2024 | 21 | $91.3M |
- D.E. Shaw & Co+520.2K (+448%)
- BlackRock+253.6K (+7%)
- Vanguard Capital Management LLC+204.0K (+12%)
- T. Rowe Price Group+169.8K (+295%)
- Dimensional Fund Advisors+69.8K (+10%)
- State Street Corp−370.1K (-16%)
- Morgan Stanley−227.0K (-16%)
- Wells Fargo & Co−100.3K (-52%)
- Citigroup−44.0K (-12%)
- Goldman Sachs Group−32.8K (-4%)
- Citadel Advisors LLC+173.9K
- Millennium Management+148.6K
- FMR LLC (Fidelity)−126.7K
- Renaissance Technologies LLC−9.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 232 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GRAL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
GRAL SEC filings: frequently asked questions
Are GRAL insiders buying or selling?
In the last 90 days, GRAIL, Inc. (GRAL) officers, directors and 10% owners reported no open-market purchases and 27 open-market sales worth $15.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GRAL stock?
As of September 30, 2026, the largest GRAIL, Inc. (GRAL) holders among the 13F filers tracked by SignalX were BlackRock ($536.7 million), State Street Corp ($282.4 million), Vanguard Capital Management LLC ($258.5 million), Morgan Stanley ($173.1 million), Bank of America Corp ($105.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GRAL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), GRAIL, Inc. (GRAL) reported revenue of $147.2 million (up 17.2% from FY2024) and a net loss of $408.4 million. Diluted EPS was -$11.11. The figures come from the XBRL data in the 10-K.
What are the main risks in GRAL's latest 10-K?
In the 10-K filed March 12, 2026, GRAIL, Inc. (GRAL) flagged: Regulatory risk from Illumina Supply Agreement royalties commencing December 24, 2026, potentially increasing costs and impacting margins. U.S. market concentration with majority Galleri sales domestically, risk from limited broad reimbursement and pricing pressure from discounts and rebates. (AI summary of the Risk Factors section.)
What did GRAL report in its latest 8-K?
GRAIL, Inc. (GRAL) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). GRAIL announced financial results for Q3 ended September 30, 2026.
What are the latest GRAL SEC filings?
GRAIL, Inc. (GRAL) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 16, 2026.
What is GRAL's SEC CIK number?
GRAIL, Inc. (GRAL)'s SEC Central Index Key (CIK) is 1699031. EDGAR lists every GRAL filing under that number.
Ask anything about GRAL
The research agent reads GRAL's filings, financials, insider trades and 13F holders, then answers with sources.